Future Medicine India – Cover Story, Medical Research News Cover Story Archives | Future Medicine India

Cover Story

Waiting for the Third Wave

On 17th May, Union Health Minister Dr Harsh Vardhan said in a press conference in New Delhi that India’s new caseload numbers for COVID-19 had dipped below the three lakh/day mark for the first time, well below the peak of four lakh/day just two weeks earlier.

Read More..

How data can help generate A public health response

The third wave of COVID 19 is imminent in India. In an article published in Nature in September 2020, it was mentioned that a typical SARS-CoV-2 virus accumulates only two single-letter mutations per month in its genome — a rate of change that is half that of influenza and one-quarter that of HIV.

Dr Monika Chaudhary

Infection after vaccination

A breakthrough case is defined as involving a person who has SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after completing the primary series of an authorised COVID-19 vaccine.


“Reinfection in vaccinated people needs to be analysed based on severity”

In a conversation with Future Medicine, Dr Madhi says he expects the next generation of vaccines that can offer a higher level of protection against all variants of SARS-CoV-2 to become available soon — probably by the 3rd quarter of 2021.


CDC reports 0.008% COVID-19 cases among fully vaccinated

In mid-April, the US Centers for Disease Control and Prevention reported about 5,800 cases of COVID-19 among Americans who have completed a full course of vaccination.


Do vaccines prevent transmission of SARS-CoV-2?

As countries around the world roll out vaccines, studies are still ongoing to determine whether COVID-19 vaccines can also stop people from getting infected and passing on the SARS-CoV-2 virus to others.



Vaccine efficacy may measure different aspects of disease like prevention of infection or preventing mild, moderate or severe disease. None of the approved COVID-19 vaccines has claimed to prevent infection and the 70-95% efficacy claimed by them is at preventing symptomatic disease